Debashish Tomar, Axel Steinbrueck, Adam C. Sedgwick, Matthew S. Levine, Jonathan L. Sessler and Nils Metzler-Nolte
{"title":"Glycosidase-activated prodrugs of a cytotoxic iron chelator for targeted cancer therapy†","authors":"Debashish Tomar, Axel Steinbrueck, Adam C. Sedgwick, Matthew S. Levine, Jonathan L. Sessler and Nils Metzler-Nolte","doi":"10.1039/D5MD00232J","DOIUrl":null,"url":null,"abstract":"<p >New glycoside-prodrugs based on the iron chelator deferasirox were designed. Selective enzymatic activation by glycosidases was observed within 24 hours, accompanied by cancer cell-selective cytotoxicity. Notably, derivative <strong>3a</strong>, bearing a β-<small>D</small>-galactose moiety, showed promising selective activity against galactosidase overexpressing OvCar-3 cells (IC<small><sub>50</sub></small> 9.1 ± 1.6 μM) while maintaining low activity against fibroblast control GM5756 cells (IC<small><sub>50</sub></small> > 100 μM).</p>","PeriodicalId":21462,"journal":{"name":"RSC medicinal chemistry","volume":" 8","pages":" 3507-3511"},"PeriodicalIF":3.6000,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12177571/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"RSC medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2025/md/d5md00232j","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
New glycoside-prodrugs based on the iron chelator deferasirox were designed. Selective enzymatic activation by glycosidases was observed within 24 hours, accompanied by cancer cell-selective cytotoxicity. Notably, derivative 3a, bearing a β-D-galactose moiety, showed promising selective activity against galactosidase overexpressing OvCar-3 cells (IC50 9.1 ± 1.6 μM) while maintaining low activity against fibroblast control GM5756 cells (IC50 > 100 μM).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
